Abstract:3-Hydroxy-3-methylglutaryl-coenzyme A reductase (HMGR) catalyzes the formation of mevalonate. In many classes of organisms, this is the committed step leading to the synthesis of essential compounds, such as cholesterol. However, a high level of cholesterol is an important risk factor for coronary heart disease, for which an effective clinical treatment is to block HMGR using inhibitors like statins. Recently the structures of catalytic portion of human HMGR complexed with six different statins have been determined by a delicate crystallography study (Istvan and Deisenhofer Science 2001, 292, 1160-1164), which established a solid basis of structure and mechanism for the rational design, optimization, and development of even better HMGR inhibitors. In this study, three-dimensional quantitative structure-activity relationship (3D QSAR) with comparative molecular field analysis (CoMFA) was performed on a training set of up to 35 statins and statin-like compounds. Predictive models were established by using two different ways: (1) Models-fit, obtained by SYBYL conventional fit-atom molecular alignment rule, has cross-validated coefficients (q2) up to 0.652 and regression coefficients (r2) up to 0.977. (2) Models-dock, obtained by FlexE by docking compounds into the HMGR active site, has cross-validated coefficients (q2) up to 0.731 and regression coefficients (r2) up to 0.947. These models were further validated by an external testing set of 12 statins and statin-like compounds. Integrated with CoMFA 3D QSAR predictive models, molecular surface property (electrostatic and steric) mapping and structure-based (both ligand and receptor) virtual screening have been employed to explore potential novel hits for the HMGR inhibitors. A representative set of eight new compounds of non-statin-like structures but with high pIC(50) values were sorted out in the present study.

Three dimensional quantitative structure activity relationship of P45017α inhibitors of 17-substituted steroids

QSAR Research of Novel Tetrandrine Derivatives Against Human Hepatocellular Carcinoma.

Structure-based Rational Quest for Potential Novel Inhibitors of Human HMG-CoA Reductase by Combining CoMFA 3D QSAR Modeling and Virtual Screening.

Exploring the Chemical Space of CYP17A1 Inhibitors Using Cheminformatics and Machine Learning

3D-QSAR Study on 2,3-Dihydroimidazo[4,5]-pyridin-2-one Derivatives with a Meta Substitution Pattern As V600E BRAF Inhibitors

3D-QSAR Study for Inhibitors of Cyclin-Dependent Kinase 4

3D QSAR Studies, Pharmacophore Modeling and Virtual Screening on a Series of Steroidal Aromatase Inhibitors.

Studies on Three-Dimensional Quantitative Structure-Activity Relationships of Nonsteroidal Progesterone Receptor Agonists 5-Benzylidene-1,2-dihydro-5h-chromeno [ 3,4-F ] Quinolines

Comparison of Steroid Substrates and Inhibitors of P-glycoprotein by 3D-QSAR Analysis

3D-QSAR study of novel liqustrazine derivatives

Receptor and ligand-based 3D-QSAR study on a series of pyrazines/pyrrolidylquinazolines as inhibitors of PDE10A enzyme

3D-QSAR study of a series of novel triazole antifungal compounds

Three-Dimensional Quantitative Structure Activity Relationship for Cyp2d6 Substrates

3D-QSAR Modeling of Phosphodiesterase-5 Inhibitors: Evaluation and Comparison of the Receptor- and Ligand-Based Alignments

3d-Qsar Study Of A Series Of Novel Benzofuran Nmt Inhibitors

Virtual identification of novel peroxisome proliferator-activated receptor (PPAR) α/δ dual antagonist by 3D-QSAR, molecule docking and molecule dynamics simulation.

Three-dimensional Vector of Pharmacophore Atomic Interaction and Its Applications to Stereoisomeric Description

3D-QSAR Research of Pteridine PI3Kγ Inhibitor

Study on the Activity of Non-Purine Xanthine Oxidase Inhibitor by 3D-Qsar Modeling and Molecular Docking

3D-QSAR Study of Statin Inhibitors of HMG-CoA Reductase

3D-QSAR and pharmacophore model study on aryl diphenolic azoles as estrogen receptor-β ligands